Chennai: Intas Pharmaceuticals claims to have made a progressive breakthrough in the antifungal Therapy domain with the launch of the ‘world’s first Super Bioavailable Itraconazole-SB 100 mg’ by the brand name of Itaspor-SB Forte/Subawin. It has been recently approved by Indian Regulatory Authorities.
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage, antacids consumption etc. and overall cost of treatment, said the company.
‘Itaspor SB Forte/Subawinis expected to improve patient compliance and reduce the Doctor’s counselling time. It will reduce dosing to half. Furthermore,patients can take it with or without a meal with just water or as directed by the physician. The cost of the therapy is also reduced substantially,’ it added.